Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.1
Alternatives to Fluoroquinolones. JAMA. 2016;316(13):1404–1405. doi:10.1001/jama.2016.8383
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: